Background. Evidence suggests that specific vaginal bacteria associated with bacterial vaginosis (BV) may increase the risk of adverse health outcomes in women. Among women participating in a randomized, double-blinded trial, we assessed the effect of periodic presumptive treatment (PPT) on detection of select vaginal bacteria.
metronidazole 750 mg with miconazole 200 mg intravaginal suppositories versus matching placebo nightly for five consecutive nights each month for 12 months to reduce rates of BV and vulvovaginal candidiasis (clinical trials registration NCT01230814). Detailed methods and results for the trial have been published elsewhere [19] . Briefly, 234 high-risk women were enrolled between May 2011 and August 2012 from 3 sites in Kenya and 1 in the United States. Eligible women were HIV-1 uninfected, 18-45 years of age, not pregnant or breastfeeding, and sexually active and had a vaginal infection at screening (BV, confirmed on the basis of the Nugent score [21] ; vulvovaginal candidiasis, on the basis of saline/potassium hydroxide wet preparation plus positive culture for yeast on Sabouraud's agar; and/or Trichomonas vaginalis infection, on the basis of a saline wet preparation). Women with symptomatic BV or with vulvovaginal candidiasis or T. vaginalis infection regardless of symptoms were provided treatment and returned for enrollment 7-14 days later. Eligible participants were randomly assigned in equal proportions to receive either the intervention or the matching placebo. All participants provided written informed consent for participation. Participants were asked to provide separate written consent for the storage and future testing of biological specimens, including those used for the present analysis. The trial was approved by the human subjects research committees at the University of Washington (Seattle), the University of Alabama at Birmingham, and the Kenyatta National Hospital (Nairobi).
At enrollment, structured face-to-face interviews were conducted to collect data on demographic, behavioral, and clinical characteristics. At monthly follow-up visits, data were collected on study product use, genital tract symptoms, sexual behaviors, intravaginal practices, and contraceptive use, and a urine pregnancy test was performed. Nonpregnant participants received a 1-month supply of study product and free male condoms. At enrollment and during follow-up visits at months 2, 4, 6, 8, 10, and 12, participants underwent a physical examination, including pelvic speculum examination, with collection of genital swabs for diagnosis of genital tract infections. Vaginal fluid was collected for polymerase chain reaction (PCR) testing of vaginal bacteria, using a push-off polyester/polyethylene terephthalate swab (FitzCo), and stored at −80°C. If a participant missed an examination visit, a physical examination was performed at her next follow-up visit.
Laboratory Procedures
Vaginal Gram-stained slides were evaluated for BV by trained technicians, using the Nugent score [21] . Vaginal swabs for bacterial quantitative PCR (qPCR) assays were transported on dry ice to the Fred Hutchinson Cancer Research Center (Seattle) for analysis. A MoBio BiOstic Bacteremia DNA Isolation kit (Carlsbad, CA) was used to extract and purify DNA. This protocol uses bead beating and chaotropic lysis to break apart bacterial cells and recover DNA that is free of PCR inhibitors. Sham extraction controls that did not contact a mucosal surface were included to monitor contamination from extraction reagents and collection swabs. All samples were subjected to 2 quality control assays. They were evaluated for PCR inhibitors, using exogenously added DNA (aequorin plasmid) and aequorin gene qPCR [22] . To verify contact of the vaginal swab with a human mucosal surface, we used a broad-range 16S rRNA qPCR assay to measure total bacterial concentrations on all samples [12] . Bacterium-specific qPCR assays were performed using purified DNA and targeted the following bacteria: Lactobacillus crispatus, Lactobacillus jensenii, Lactobacillus iners, BV-associated bacterium 1 (BVAB1), BVAB2, Mageeibacillus indolicus, Atopobium vaginae, Leptotrichia/Sneathia species, Megasphaera species, and Gardnerella vaginalis, as previously described [23, 24] . No-template water controls were included with all PCR runs, to monitor contaminants from PCR reagents.
Statistical Analysis
Our primary objectives were to assess the effect of the PVI trial intervention on detection and concentrations of vaginal bacteria associated with vaginal health or BV, using a modified intent-to-treat approach. Participants were excluded from the analysis if they did not consent to future testing of stored specimens or if they did not return for any follow-up visits. Enrollment characteristics, stratified by study arm, were summarized using descriptive statistics, and differences were assessed using χ 2 analysis or the Fisher exact test (where appropriate) for categorical factors and the Wilcoxon rank sum test for continuous factors. For each bacterium, the proportion of follow-up visits with detectable quantities (ie, values above the lower limit of detection [LLD] ) was calculated by arm. Relative risks (RRs) were generated using generalized estimating equations with a log link and exchangeable correlation structure to separately assess the effect of the intervention on species detection. Evidence suggests that the vaginal microbiota may differ by geographic region [25] . In addition, there were differences by country in key baseline factors known to be associated with BV in the primary analysis. To investigate the potential impact of these differences on our primary results, we performed a secondary analysis stratifying by country. Per protocol, study product was withheld if a participant tested positive for pregnancy; therefore, we performed a sensitivity analysis that excluded visits where pregnancy was detected.
Since we used qPCR assays, which provide bacterial concentrations (rather than broad-range PCR with sequencing, which provides relative abundance), we planned to assess the impact of the intervention on bacterial concentration in addition to detection. The qPCR assays used in this study are highly sensitive and can detect bacterial quantities as low as 94 (log 10 1.97) copies/ swab. However, for many of the bacteria assessed, a large proportion of specimens had values below the LLD, precluding analyses using linear regression models, owing to an excessive number of samples with values below the LLD for some species. In addition, the range of quantities detected was quite large (Supplementary Table 1 ). Data are limited concerning the relationship between BV and the quantity of specific bacterial species. Therefore, we performed an exploratory analysis to evaluate changes in species quantities that may have a clinically meaningful relationship to BV. We used baseline data from all participants to generate receiver operating characteristic (ROC) curves of the log 10 quantity of species versus the presence of BV by Nugent score at enrollment in order identify a quantity threshold that was predictive of BV. For each species, we noted the log 10 quantity corresponding (15) 23 (21) 12 (23) 27 (16) Condoms only 30 (27) 31 (28) 11 (21) 50 (30) Oral contraceptives 12 (11) 11 (10) 5 (9) 18 (11) Injectable contraceptives 25 (23) 24 (22) 3 (6) 46 (27) Intrauterine device 10 (9) 4 (4) 4 (8) 10 (6) Implant 9 (8) 5 (5) 1 (2) 13 (8) Tubal ligation 5 (5) 10 (9) 14 (26) 1 (1) Other c 3 (3) 3 (3) 3 (6) 3 (2) Currently smoke cigarettes 10 (9) 20 (18) . 05 18 (34) 12 (7) <.001
Vaginal washing in the past month 55 (50) Sexual behaviors in the past week
Unprotected sex .40 .13
No sex 20 (18) 21 (19) 10 (19) 31 (18) 100% condom use 53 (48) 42 (38) 19 (36) 76 (45) Intermittent condom use 11 (10) 12 (11) 3 (6) 20 (12) No condom use 26 (24) 36 (32) 21 (40) 41 (24) No. of partners
New partner 23 (21) 22 (20 c Other includes Essure, Bayer (n = 1), fertility awareness method (n = 2), herbal pill (n = 1), partner vasectomy (n = 1), and withdrawal (n = 1).
d Two of the sites in Kenya recruited participants from longitudinal cohort studies following women who reported a history of engaging in transactional sex.
e Kenyan participants with an optical density >2.1 were considered positive for herpes simplex virus type 2 (HSV-2).
f One participant from Mombasa site missing baseline TV result. TV by NAAT.
g Defined as ≥30 polymorphonuclear cells per high-powered field. One participant from the US was missing a result.
to the highest proportion correctly classified as being BV positive or BV negative on the basis of the Nugent score and calculated the sensitivity and specificity for BV at that quantity value. We use the term "ROC cutoff " to refer to this value. A similar approach has been used in other areas of public health to assess relationships between organism burden and clinical disease [26] . The same statistical methods used for the primary analysis were implemented to repeat our analyses, using the ROC cutoff as the outcome. All statistical tests were assessed using a 2-sided significance level of 0.05. Analyses were conducted using Stata, version 14·0 (StataCorp, College Station, TX).
RESULTS
Of the 234 participants enrolled, 232 (99%) returned for at least 1 follow-up visit, of whom 221 (95%; 111 [50%] in the intervention arm and 110 [50%] in the placebo arm) provided consent for future testing of stored specimens. Demographic, behavioral, and clinical characteristics at enrollment are presented by study arm and by country in Table 1 . Characteristics of participants in the intervention arm were generally similar to those in the placebo arm. Participant follow-up did not differ by study arm, with 87% of participants in the intervention arm attending ≥80% scheduled study visits, compared with 89% of participants in the placebo arm (P = .55). In contrast, a number of baseline characteristics differed between US and Kenyan participants (Table 1) . At enrollment, the proportion of participants with bacterial quantities below the LLD cutoff did not differ by arm (Table 2, Figure 1 ). Overall, L. iners and G. vaginalis were the most prevalent species at enrollment (88.2% and 92.8% of visits, respectively), while L. jensenii and BVAB1 were the least prevalent (20.8% and 21.7%, respectively). Bacterial detection at enrollment differed by country, with a higher proportion of US participants having detectable levels of L. jensenii, L. iners, BVAB1, and M. indolicus as compared to Kenyan participants (Table 2, Figure 1) .
In unadjusted bacterium-specific models, the proportion of follow-up visits with BV-associated species at levels below the LLD was lower in the PPT arm, compared with the placebo arm, for the following bacteria: BVAB1, BVAB2, A. vaginae, Leptotrichia/Sneathia species, and Megasphaera species ( Table 3 ). The proportion of visits with L. crispatus, L. jensenii, or L. iners was higher for each species, but these increases were smaller in magnitude and not statistically significant. Results were similar after adjustment for study site (Table 3 ) and were also similar in a sensitivity analysis excluding visits where participants were pregnant and did not receive study product (data not shown). In analyses stratified by country, among Data no. (%) of women. ROC curves, proportion correctly classified at the specified cutoff, sensitivity, and specificity are presented in Supplementary Figure 1 and Supplementary Table 1. M-H was used for the P value between study arms and chi-square was used for P value by country. This applies to both LLD and ROC cut-offs Kenyan participants we observed reductions in the proportion of visits with values below the LLD in the intervention arm, compared with the placebo arm, for BVAB1, BVAB2, A. vaginae, Leptotrichia/Sneathia species, Megasphaera species, and M. indolicus. However, among US participants the effect sizes were smaller in magnitude, with no significant differences by arm ( Figure 2 and Supplementary Table 2 ). In light of these differences by country, we explored self-reported adherence by country and observed that 99% of Kenyan participants reported using all 5 doses of study product at each visit where product was dispensed, compared with 88% of US participants (P < .001).
In our exploratory analysis that assessed the impact of the intervention on the proportion of species with bacterial quantities at or above the ROC cutoff, we noted a wide range of cutoffs (Table 2) . Consistent with the primary analysis, no differences were noted by study arm at enrollment. However, a higher proportion of US participants also had quantities at or above the ROC cutoff for L. jensenii, L. iners, BVAB1, and M. indolicus, compared with Kenyan participants. Similar to the primary analysis, we observed significant decreases in the proportion of visits with bacterial quantities at or above the ROC cutoff among women in the intervention arm, compared with those in the placebo arm. The effect sizes were generally larger for the ROC cutoff analysis as compared to the analysis of quantities above the LLD. After we stratified by country, again there was an increase in the proportion of samples in the intervention arm with an L. iners value at or above the ROC cutoff and decreases in almost all BV-associated species among Kenyan participants in the intervention arm, compared with no differences among US participants (Figure 2 and Supplementary Table 2 ).
DISCUSSION
Use of monthly periodic presumptive treatment for 1 year significantly reduced colonization with several bacteria strongly associated with BV. In addition, the magnitude of the decrease in the proportion of women in the intervention arm with quantities at or above the ROC cutoff for BV-associated species was greater than the magnitude of the decrease observed using the LLD. Given that the ROC cutoffs for BV-associated species represented high quantities, ranging from log 10 6.59 to log 10 8.84, these decreases are indicative of reductions in bacterial quantity (ie, although the bacterium was still present, fewer women had higher quantities of bacteria). The intervention reduced detection and quantities of BVAB2 and Megasphaera species, 2 bacteria associated with both BV persistence and recurrence [24, a The numerator represents the number of follow-up visits where the bacteria of interest was detected at levels above the LLD, and the denominator is the number of follow-up visits with microbiome testing.
b Data are from generalized estimating equations with a log link and exchangeable correlation structure and clustered by participant.
c Data are from generalized estimating equations with a log link and exchangeable correlation structure and clustered by participant, with adjustment for study site. 
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]. Other studies of suppressive therapy have noted that the treatment effect wanes following cessation of the intervention [5, 6] . Further research is required to understand the durability of changes in bacterial concentrations following cessation of the intervention and their impact on subsequent BV risk. Consistent with observations following standard treatment for BV, decreases in detection and quantity (at or above the ROC cutoff) of A. vaginae were also observed. It is hypothesized that A. vaginae may have limited susceptibility to metronidazole, depending on the strain [28, 29] . In the absence of susceptibility testing, our data suggest that A. vaginae may be susceptible to metronidazole or that A. vaginae may be reliant on the presence of other species in the community and their metabolites for survival. As a result, alterations in the larger community composition may impact A. vaginae detection and quantity. Our analysis shows that metronidazole use is associated with decreased concentrations of A. vaginae. Based on observations from prior studies suggesting differences in the vaginal microbiota in different geographic regions and the fact that a number of demographic and behavioral factors associated with BV differed by country, we repeated our analyses, stratified by country. At enrollment, we observed notable differences in species colonization, with lower frequencies of Lactobacillus species and some BV-associated species among Kenyan women as compared to US women (the majority of whom were African American). With regard to the intervention effect, more-pronounced decreases in BV-associated bacteria were observed among Kenyan women, while the effect sizes among US women were attenuated and no longer statistically significant. It is possible that differences by geographic region in BV-associated risk behaviors and bacterial colonization contributed to the differential effectiveness of the intervention [30] . Alternatively, uptake of the intervention is likely to influence the vaginal microbiome. When study product use was evaluated, it was noted that a higher proportion of Kenyan women reported using all 5 does at visits where study product was dispensed, compared with findings observed for US women. It is possible that differences in adherence and in BV-associated behaviors by country modified the impact of the intervention. The prevalence of BV has been observed to be higher among African and African American women, compared with women from other regions and women of other races, respectively [1, 31] . Broad-range PCR analysis of vaginal samples has also demonstrated differences in bacterial communities by racial category, with African American women having a higher prevalence of communities dominated by anaerobic species, compared with women of European ancestry [32, 33] . Few studies have directly compared the vaginal microbiota of women living in different geographic regions, using molecular methods [25, 34] . The prevalence of L. crispatus, L. jensenii, and L. iners among Kenyan women was generally similar to the prevalence reported in a cross-sectional study of South African, Rwandan, and Kenyan women [34] . In contrast, at enrollment, nearly 95% of Kenyan women in our study had measureable quantities of G. vaginalis, compared with 45%-73% in the multicountry African study, despite having a similar prevalence of BV in both studies. Of note, we observed a higher prevalence of BVAB1 among US women, which is consistent with reports from others, who noted that BVAB1 was detected more frequently among African American women as compared to women of European ancestry [33] . Interestingly, BVAB1 was detected less frequently among Kenyan women, suggesting that geographic region (and factors associated with region) also influence species prevalence. However, with these comparisons, it is important to note that differences in laboratory methods between published studies may impact the ability to directly compare findings.
Our analysis included several strengths, including data collected as part of a multisite, multicountry clinical trial, which allowed for comparisons across 2 distinct geographic regions. The intervention was evaluated among women with a recent vaginal infection, as they would be most likely to benefit from a vaginal health intervention. Nonetheless, our findings should be interpreted in the context of several limitations. Study participants were predominantly African or African American. As a result, we had limited ability to explore the impact of race, beyond comparing African versus African American, as an effect modifier. Several additional features of our study population are important to consider and could impact the generalizability of our findings, including diagnosis of a vaginal infection at screening and frequent reporting of transactional sex history. This analysis assessed the impact of the intervention on select species that are strongly associated with the presence or absence of BV. However, the intervention likely affected the overall vaginal microbiota, which is not well assessed using qPCR assays. Many samples had values below the LLD, limiting our ability to evaluate changes in bacterial quantity by study arm. To address this limitation, the use of predictive methods to determine thresholds based on ROC curves provided a novel approach to addressing the issue of changes in bacterial quantity associated with a clinical outcome. The PVI trial was powered to assess the effect of the PPT intervention on BV and vulvovaginal candidiasis. As a result, statistical power was insufficient to detect smaller shifts in the prevalence of individual bacterial species, especially in analyses stratified by country.
In summary, monthly periodic presumptive treatment for 1 year has previously been shown to reduce overall detection of BV. The present analysis extends the findings of the original trial by showing that this PPT regimen also reduces detection and concentrations of species that are highly predictive of BV persistence and recurrence, including BVAB2, A. vaginae, Leptotrichia/Sneathia species, and Megasphaera species. Several approaches were used to assess the impact of the intervention on vaginal bacteria with similar results, highlighting the robustness of our findings. In light of recent findings demonstrating associations between detection of specific vaginal bacteria and increased risk of HIV-1 infection and preterm birth [14, 26] , the role of PPT to improve vaginal health and reduce these adverse health outcomes in women should be explored.
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